GlassScriptPhysician profile
Zanetta R Bryant
NPI 1114332657
$10,689.52
in general payments reported to CMS, 2019-2025
58 companies · $557 in 2025
The $557 reported for 2025 was more than what 77% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,785 · 2022: $3,165 · 2023: $2,693 · 2024: $1,490 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,663 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,663.39 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,299.62 | 2021-2025 | |
| Ucb, INC. | $869.98 | 2021-2025 | Briviact, Rystiggo, Zilbrysq |
| Sk Life Science, INC. | $575.80 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $564.99 | 2021-2025 | |
| Mdd US Operations, LLC | $523.65 | 2022-2025 | Gocovri, Gocovri |
| Neurocrine Biosciences, INC. | $460.26 | 2021-2024 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $437.06 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Acadia Pharmaceuticals INC | $432.88 | 2021-2025 | Nuplazid |
| Argenx US, INC. | $420.94 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Kyowa Kirin, INC. | $335.02 | 2021-2024 | Nourianz |
| Neurelis, INC. | $320.35 | 2021-2025 | Valtoco |
| Lilly USA, LLC | $293.27 | 2022-2024 | Emgality, Amyvid |
| Sunovion Pharmaceuticals INC. | $291.73 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $291.38 | 2022 | |
| Amneal Pharmaceuticals LLC | $245.96 | 2021-2023 | Lyvispah, Rytary |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zanetta Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.